5/7/2013

India's Drug Controller General office announced plans to inspect all of the nation's clinical-trial sites at least annually to verify regulatory compliance. The inspections will cover Schedule Y drugs and cosmetics, good clinical practice and other regulatory requirements. The move follows criticism of the agency's failure to monitor human clinical trials more closely and is part of several other recent measures, including establishing an ethics committee and setting guidelines for compensation to those injured in clinical trials.

Related Summaries